// January In January, XyloCor’s gene therapy showed promise for cardiovascular conditions, a reanalysis raised concerns about Amgen’s Repatha, Renibus’ cardiac surgery drug succeeded in a phase 2 trial, and AstraZeneca announced a $1.8 billion acquisition in the cardiovascular field....